Age of Parkinson's disease onset as a predictor for the development of dyskinesia

Movement Disorders

Volumn 25, Issue 9, 2010, Pages 1177-1182

  Ku, Stephen ^a,b   Glass, Graham A ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Age of onset; Dyskinesia; Parkinson's disease

Indexed keywords

LEVODOPA;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL DECISION MAKING; DYSKINESIA; HUMAN; MAJOR CLINICAL STUDY; ONSET AGE; PARKINSON DISEASE; PREDICTOR VARIABLE; PRIORITY JOURNAL; RISK ASSESSMENT; AGE; DYSKINESIA, DRUG-INDUCED; FEMALE; KAPLAN MEIER METHOD; LONGITUDINAL STUDY; MALE; MIDDLE AGED; MORTALITY; PARKINSONIAN DISORDERS; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; VERY ELDERLY;

ADULT; AGE FACTORS; AGE OF ONSET; AGED; AGED, 80 AND OVER; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEVODOPA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PARKINSONIAN DISORDERS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 77955075900     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23068     Document Type: Article

References (17)

1. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002;58:11-17. (Pubitemid 34041931)
2. Weiner WJ. Initial treatment of Parkinson disease: levodopa or dopamine agonists. Arch Neurol 2004;61:1966-1969. (Pubitemid 39612963)
3. Albin RL, Frey KA. Initial agonist treatment of Parkinson disease: a critique. Neurology 2003;60:390-394. (Pubitemid 36188231)
4. Schapira AH, Olanow CW. Drug selection and timing of initiation of treatment in early Parkinson's disease. Ann Neurol 2008;64 (Suppl 2):S47-S55.
5. Silver DE. Early, nondisabling Parkinson's disease: weighing the options for initial therapy. Neurol Clin 2008;26:(3 Suppl)S1-S13.
6. Parkinson Study Group CALM Cohort Investigators. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol 2009;66:563-570.
7. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004;61:1044-1053. (Pubitemid 38915945)
8. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;342:1484-1491.
9. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-458.
10. Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990. Arch Neurol 2006;63:205-209.
11. Grandas F, Galiano ML, Tabernero C. Risk factors for levodopa-induced dyskinesias in Parkinson's disease. J Neurol 1999;246:1127-1133. (Pubitemid 30021235)
12. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 2000;123:2297-2305.
13. Kumar N, Van Gerpen JA, Bower JH, Ahlskog JE. Levodopa-dyskinesia incidence by age of Parkinson's disease onset. Mov Disord 2005;20:342-344. (Pubitemid 40613295)
14. Silver D. Impact of functional age on the use of dopamine agonists in patients with Parkinson disease. Neurologist 2006;12:214-223. (Pubitemid 44134047)
15. Katzenschlager R, Head J, Schrag A, Ben-Shlomo Y, Evans A, Lees AJ. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 2008;71:474-480.
16. Hauser RA, Rascol O, Korczyn AD, et al. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 2007;22:2409-2417.
17. Zappia M, Annesi G, Nicoletti G, et al. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study. Arch Neurol 2005;62:601-605.